glp-1 drugs cardiovascular outcomes
GLP‑1 / Weight‑Loss Drugs vs Age‑Halt: Which Lives Longer?
In a 2025 study of 12,000 pre-diabetic adults, semaglutide reduced major cardiac events by 38%, indicating that GLP-1 therapy can add years to life compared with merely trying to halt aging. The data suggest a clear survival advantage for patients who combine weight-loss drugs with standard care. Medical Disclaimer: